Header

UZH-Logo

Maintenance Infos

Ranibizumab and Aflibercept for the Treatment of Pigment Epithelial Detachment in Neovascular Age-Related Macular Degeneration: Data from an Observational Study


Vaze, Anagha; Nguyen, Vuong; Daien, Vincent; Arnold, Jennifer J; Young, Stephanie H; Cheung, Chui M; Lamoureux, Ecosse; Bhargava, Mayuri; Barthelmes, Daniel; Gillies, Mark C; Fight Retinal Blindness Study Group (2018). Ranibizumab and Aflibercept for the Treatment of Pigment Epithelial Detachment in Neovascular Age-Related Macular Degeneration: Data from an Observational Study. Retina, 38(10):1954-1961.

Abstract

Purpose:
To assess the effect of intravitreal ranibizumab and aflibercept on retinal pigment epithelial detachment (RPED) in patients with neovascular age-related macular degeneration.
Methods:
This was a retrospective analysis of data from a prospectively designed and implemented clinical audit. Analysis included change in RPED dimensions and visual acuity in 92/233 treatment-naive eyes with neovascular age-related macular degeneration and RPED 6 months after treatment with either aflibercept or ranibizumab.
Results:
There was no significant between-group difference in the adjusted mean change for maximum RPED height (P = 0.195), diameter (P = 0.522) or visual acuity (P = 0.836) at 6 months. Injection frequency was the only clinical variable that affected RPED height (P = 0.050) and visual acuity change for both treatment groups (P = 0.004). Around 30% of eyes in each group had complete resolution of RPED at 6 months.
Conclusion:
Eyes with neovascular age-related macular degeneration and RPED showed significant functional and anatomical responses after 6 months of intravitreal anti–vascular endothelial growth factor injections. However, we found no significant difference in anatomical response or change in visual acuity between eyes treated with ranibizumab compared with aflibercept. Larger, prospectively designed, randomized studies with longer term follow-up may identify a difference between the two drugs that we did not detect.

Abstract

Purpose:
To assess the effect of intravitreal ranibizumab and aflibercept on retinal pigment epithelial detachment (RPED) in patients with neovascular age-related macular degeneration.
Methods:
This was a retrospective analysis of data from a prospectively designed and implemented clinical audit. Analysis included change in RPED dimensions and visual acuity in 92/233 treatment-naive eyes with neovascular age-related macular degeneration and RPED 6 months after treatment with either aflibercept or ranibizumab.
Results:
There was no significant between-group difference in the adjusted mean change for maximum RPED height (P = 0.195), diameter (P = 0.522) or visual acuity (P = 0.836) at 6 months. Injection frequency was the only clinical variable that affected RPED height (P = 0.050) and visual acuity change for both treatment groups (P = 0.004). Around 30% of eyes in each group had complete resolution of RPED at 6 months.
Conclusion:
Eyes with neovascular age-related macular degeneration and RPED showed significant functional and anatomical responses after 6 months of intravitreal anti–vascular endothelial growth factor injections. However, we found no significant difference in anatomical response or change in visual acuity between eyes treated with ranibizumab compared with aflibercept. Larger, prospectively designed, randomized studies with longer term follow-up may identify a difference between the two drugs that we did not detect.

Statistics

Citations

Altmetrics

Downloads

48 downloads since deposited on 13 Oct 2017
47 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Ophthalmology Clinic
Dewey Decimal Classification:610 Medicine & health
Uncontrolled Keywords:Ophthalmology, General Medicine
Language:English
Date:October 2018
Deposited On:13 Oct 2017 07:11
Last Modified:06 Jan 2019 06:38
Publisher:Lippincott Williams & Wilkins
ISSN:0275-004X
OA Status:Green
Publisher DOI:https://doi.org/10.1097/IAE.0000000000001815
PubMed ID:28820848

Download

Download PDF  'Ranibizumab and Aflibercept for the Treatment of Pigment Epithelial Detachment in Neovascular Age-Related Macular Degeneration: Data from an Observational Study'.
Preview
Content: Published Version
Filetype: PDF
Size: 99kB
View at publisher